Gender Differences in Prevalence and Clinical Correlates of Lipohypertrophy in Insulin-Exposed Patients with Diabetes Mellitus

References

• Saeedi P, Petersohn I, Salpea P., et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Wang L, Peng W, Zhao Z, et al. Prevalence and treatment of diabetes in China, 2013-2018. JAMA. 2021;326(24):2498–2506. doi:10.1001/jama.2021.22208
   PubMed Web of Science ®Google Scholar
• Gentile S, Strollo F, Ceriello A. Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: are we sure everything is clear? Diabetes Therapy. 2016;7(3):401–409. doi:10.1007/s13300-016-0187-6
   PubMed Web of Science ®Google Scholar
• De Coninck C, Frid A, Gaspar R, et al. Results and analysis of the 2008–2009 insulin injection technique questionnaire survey. J Diabetes. 2010;2(3):168–179. doi:10.1111/j.1753-0407.2010.00077.x
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang S, Liu C, et al. A meta-analysis and meta-regression on the prevalence of lipohypertrophy in diabetic patients on insulin therapy. Therapies. 2021;76(6):617–628. doi:10.1016/j.therap.2021.04.002
   Web of Science ®Google Scholar
• Strollo F, Guarino G, Armentano V. Unexplained hypoglycaemia and large glycaemic variability: skin lipohypertrophy as a predictive sign. Diabetes Res Open J. 2016;2(1):24–32. doi:10.17140/DROJ-2-126
   Google Scholar
• Gentile S, Strollo F, Guarino G, et al. Why are so huge differences reported in the occurrence rate of skin lipohypertrophy? Does it depend on method defects or on lack of interest? Diabetes Metabolic Syndrome. 2019;13(1):682–686. doi:10.1016/j.dsx.2018.11.042
   Web of Science ®Google Scholar
• Pahuja V, Punjot P, Fernandes G, et al. Exploring the factors associated with lipohypertrophy in insulin-treated type 2 diabetes patients in a tertiary care hospital in Mumbai, India. Int J Diabetes Dev Ctries. 2019;39(3):426–431. doi:10.1007/s13410-019-00735-0
   Web of Science ®Google Scholar
• Blanco M, Hernández MT, Strauss KW, et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39(5):445–453. doi:10.1016/j.diabet.2013.05.006
   PubMedGoogle Scholar
• Spollett G, Edelman SV, Mehner P, et al. Improvement of insulin injection technique: examination of current issues and recommendations. Diabetes Educ. 2016;42(4):379–394. doi:10.1177/0145721716648017
   PubMed Web of Science ®Google Scholar
• Famulla S, Hövelmann U, Fischer A, et al. Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control. Diabetes Care. 2016;39(9):1486–1492. doi:10.2337/dc16-0610
   PubMed Web of Science ®Google Scholar
• Gentile S, Guarino G, Corte TD, et al. Insulin-induced skin lipohypertrophy in type 2 diabetes: a multicenter regional survey in Southern Italy. Diabetes Therapy. 2020;11(9):2001–2017. doi:10.1007/s13300-020-00876-0
   Web of Science ®Google Scholar
• Deng N, Zhang X, Zhao F, et al. Prevalence of lipohypertrophy in insulin‐treated diabetes patients: a systematic review and meta‐analysis. J Diabetes Investig. 2018;9(3):536–543. doi:10.1111/jdi.12742
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372():n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Quality assessment tool for observational cohort and cross-sectional studies; 2014. Available from: https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort. Accessed December 4, 2017.
   Google Scholar
• Ryan R, Hill S How to GRADE the quality of the evidence. Version 3.0; 2016. Available from: http://cccrg.cochrane.org/author-resources. Accessed Dec 4, 2017.
   Google Scholar
• Hernar I, Haltbakk J, Broström A. Differences in depression, treatment satisfaction and injection behaviour in adults with type 1 diabetes and different degrees of lipohypertrophy. J Clin Nurs. 2017;26:4583–4596. doi:10.1111/jocn.13801
   Web of Science ®Google Scholar
• Ji L, Sun Z, Li Q, et al. Lipohypertrophy in China: prevalence, risk factors, insulin consumption, and clinical impact. Diabetes Technol Ther. 2017;19(1):61–67. doi:10.1089/dia.2016.0334
   PubMed Web of Science ®Google Scholar
• Lin Y, Lin L, Wang W, et al. Insulin-related lipohypertrophy: ultrasound characteristics, risk factors, and impact of glucose fluctuations. Endocrine. 2022;75(3):768–775. doi:10.1007/s12020-021-02904-w
   Web of Science ®Google Scholar
• Arora S, Agrawal NK, Shanthaiah DM, et al. Early detection of cutaneous complications of insulin therapy in type 1 and type 2 diabetes mellitus. Prim Care Diabetes. 2021;15(5):859–864. doi:10.1016/j.pcd.2021.06.004
   Web of Science ®Google Scholar
• Gentile S, Guarino G, Della Corte T, et al. Bruising: a neglected, though patient-relevant complication of insulin injections coming to light from a real-life nationwide survey. Diabetes Therapy. 2021;12(4):1143–1157. doi:10.1007/s13300-021-01026-w
   Web of Science ®Google Scholar
• Thewjitcharoen Y, Prasartkaew H, Tongsumrit P, et al. Prevalence, risk factors, and clinical characteristics of lipodystrophy in insulin-treated patients with diabetes: an old problem in a new era of modern insulin. Diabetes Metab Syndrome Obesity. 2020;13:4609. doi:10.2147/DMSO.S282926
   PubMed Web of Science ®Google Scholar
• Lian L, Fu Jingling, Longyan F. Investigation on the current situation and related factors of subcutaneous fat hyperplasia in diabetic patients with insulin injection. Nursing Practice Res. 2018;15(7):18–20.
   Google Scholar
• Tsadik AG, Atey TM, Nedi T, et al. Effect of insulin-induced lipodystrophy on glycemic control among children and adolescents with diabetes in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. J Diabetes Res. 2018;2018:1–7. doi:10.1155/2018/4910962
   Web of Science ®Google Scholar
• Al Hayek AA, Robert AA, Braham RB, et al. Frequency of lipohypertrophy and associated risk factors in young patients with type 1 diabetes: a cross-sectional study. Diabetes Therapy. 2016;7(2):259–267. doi:10.1007/s13300-016-0161-3
   Web of Science ®Google Scholar
• Sawatkar GU, Kanwar AJ, Dogra S, et al. Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 South Asian patients. Br J Dermatol. 2014;171(6):1402–1406. doi:10.1111/bjd.13077
   Web of Science ®Google Scholar
• Singha A, Bhattacharjee R, Dalal BS, et al. Associations of insulin-induced lipodystrophy in children, adolescents, and young adults with type 1 diabetes mellitus using recombinant human insulin: a cross-sectional study. J Pediatric Endocrinol Metabo. 2021;34(4):503–508. doi:10.1515/jpem-2020-0556
   Web of Science ®Google Scholar
• McCann A. Frequency of injection site assessment for lipohypertrophy in children and young people with type 1 diabetes. Nurs Child Young People. 2022;34(4):548.
   Google Scholar
• Conwell LS, Pope E, Artiles AM, et al. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr. 2008;152(5):622–628. doi:10.1016/j.jpeds.2007.10.006
   Web of Science ®Google Scholar
• Dan Y, Min Z, Yue W, et al. Analysis of influencing factors of subcutaneous fat hyperplasia caused by insulin injection based on accurate ultrasonic detection. Chine J Diabetes. 2021;29(10):738–741.
   Google Scholar
• Barola A, Tiwari P, Bhansali A, et al. Insulin-related lipohypertrophy: lipogenic action or tissue trauma? Front Endocrinol (Lausanne). 2018;9:638. doi:10.3389/fendo.2018.00638
   Web of Science ®Google Scholar
• Gupta SS, Gupta KS, Gathe SS, et al. Clinical implications of lipohypertrophy among people with type 1 diabetes in India. Diabetes Technol Ther. 2018;20(7):483–491. doi:10.1089/dia.2018.0074
   Web of Science ®Google Scholar
• Omar MA, El-Kafoury AA, El-Araby RI. Lipohypertrophy in children and adolescents with type 1 diabetes and the associated factors. BMC Res Notes. 2011;4(1):290. doi:10.1186/1756-0500-4-290
   Google Scholar
• Vardar B, Kızılcı S. Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract. 2007;77(2):231–236. doi:10.1016/j.diabres.2006.12.023
   PubMed Web of Science ®Google Scholar
• Chundan T. Study on the related factors of subcutaneous fat hyperplasia caused by insulin treatment of gestational diabetes. Shanghai Nursing. 2019;1:548.
   Google Scholar
• Yi Y, Yihua J, Xiaowen C. Study on the related factors of subcutaneous fat hyperplasia caused by insulin injection in the treatment of gestational diabetes. J Clin Exp Med. 2021;20(12):4.
   Google Scholar
• Lombardo F, Bombaci B, Alibrandi A, et al. The impact of insulin-induced lipodystrophy on glycemic variability in pediatric patients with type 1 diabetes. Children. 2022;9(7):1087. doi:10.3390/children9071087
   PubMedGoogle Scholar